Orphazyme A/S (ORPH) News Today → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Free ORPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 7, 2024 | foxnews.comSome Alzheimer's cases may be caused by copies of a single gene, research showsMay 7, 2024 | nytimes.comStudy Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’sMay 7, 2024 | abcnews.go.comA gene long thought to just raise the risk for Alzheimer's may cause some casesMay 6, 2024 | msn.comGenes known to increase the risk of Alzheimer’s may actually be an inherited form of the disorder, researchers sayMay 6, 2024 | msn.comScientists may have found a way to make a universal donor bloodMay 3, 2024 | yahoo.comAllozymes puts its accelerated enzymatics to work on a data and AI play, raising $15MMay 2, 2024 | msn.comRapamycin shows promise in slowing Alzheimer's disease progression linked to seizuresMay 1, 2024 | msn.comOrgan transplant drug may slow Alzheimer's disease progressionApril 30, 2024 | msn.comStrategic Innovation in SARMs: OTR-AC's Esterification AdvantageApril 27, 2024 | msn.comOrpheus Pledger was on SAS Australia for a 'redemption arc'. Now there's been a manhunt for him.April 20, 2024 | msn.comPhase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patientsApril 19, 2024 | msn.comOlympic torch makes Acropolis overnight stop a week before handover to Paris organizersApril 18, 2024 | nbcnews.comInside Gen Alpha’s controversial obsession with skincareApril 13, 2024 | msn.comIt’s the first drug shown to slow Alzheimer’s. Why is is it off to a slow start?April 12, 2024 | msn.comLysine Is Important for the Body, and Is Generally a Safe SupplementApril 11, 2024 | markets.businessinsider.comZevra Therapeutics: Strong Buy on Strategic Financing and Promising Drug PortfolioApril 8, 2024 | msn.comFrom fungi to feast: The rise of Mycoprotein as a sustainable protein solutionApril 3, 2024 | msn.comAsk A Doctor: What Diseases Cause Encephalopathy?April 1, 2024 | msn.comChemists discover a key protein in how lysosomes workMarch 28, 2024 | msn.comOrry refuses to shake woman’s hand citing ‘germs,’ threatens legal action after her videoMarch 28, 2024 | msn.comA Guide To Pokémon's Poison TypeMarch 18, 2024 | msn.comUnderstanding what causes trastuzumab's cardiotoxicityMarch 16, 2024 | msn.comHow a brash, red-haired orphan from P.E.I. continues to be a worldwide sensationMarch 14, 2024 | msn.comSindica - A Novel, Patented Post-emergence Herbicide for Sugarcane from AtulMarch 12, 2024 | msn.comSharing a Drink With Orphaned Opossum BabiesMarch 12, 2024 | msn.comZevra adds bull at William Blair despite delay in arimoclomol decisionMarch 11, 2024 | msn.com'Why haven't they shown us the original photo?' Anti-monarchist FUMES over Kate's apology - ‘Doesn't explain anything’March 10, 2024 | nytimes.comA.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the MarketMarch 5, 2024 | msn.comAlnylam’s experimental drug for high blood pressure yields encouraging resultsMarch 4, 2024 | marketwatch.comFDA Extends Review of Zevra's Arimoclomol by Three MonthsFebruary 23, 2024 | msn.comLadybug scents offer a more ecologically friendly way to protect cropsFebruary 23, 2024 | msn.comGen Alpha have a say on which names they consider to be 'old'February 23, 2024 | yahoo.comOne Piece: Is S-Hawk the Strongest Seraphim in the Series?February 22, 2024 | msn.comWhat Is The History Of Phenylketonuria? A Review By DoctorsJanuary 31, 2024 | msn.comNew Horizons in Chemical Biology: A Novel Approach to Synthesize Dibenzothiophene S-OxidesJanuary 31, 2024 | msn.comChemical biology: A novel approach to synthesize dibenzothiophene s-oxidesDecember 5, 2023 | markets.businessinsider.comLevi & Korsinsky, LLP Notifies Shareholders of Orphazyme (ORPH) an Upcoming Claims Deadline in a Class Action SettlementNovember 4, 2023 | msn.comWhat is Suboxone? Web sleuths speculate possible role of drug in Matthew Perry's hot tub death amid delayed toxicology reportNovember 3, 2023 | msn.comMonkeypox ‘circulating for five years’ before 2022’s global health emergencyOctober 29, 2023 | msn.comMatthew Perry's autopsy has been completed but results are pending a toxicology reportAugust 24, 2023 | msn.comOne Piece Reveals The Seraphim's Surprising WeaknessAugust 23, 2023 | msn.comWhat’s Going Around: poison oakAugust 21, 2023 | nypost.comAlpha-gal syndrome: LI county a hot spot for tick-borne meat allergyAugust 18, 2023 | msn.comUS FDA approves higher dose of Regeneron's eye disease drug EyleaAugust 17, 2023 | investing.comOrphazyme A/S (ORPHA)August 8, 2023 | yahoo.comRaven-Symoné suffered a seizure after having breast reductions, liposuction before turning 18August 7, 2023 | marketwatch.comVistaGen's Fasedienol Trial For Social Anxiety Meets Primary EndpointAugust 7, 2023 | markets.businessinsider.comAstellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell TherapyJuly 28, 2023 | cbsnews.comUp to 450,000 in U.S. have red meat allergies due to alpha-gal syndrome spread by ticks, CDC saysJuly 23, 2023 | msn.comHow to avoid contracting typhus, a bacterial infection spread through fleas Get Orphazyme A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPH and its competitors with MarketBeat's FREE daily newsletter. Email Address CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it. Click on Adam's shiny forehead for more details. ORPH Media Mentions By Week ORPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORPH News Sentiment▼-0.020.42▲Average Medical News Sentiment ORPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORPH Articles This Week▼01▲ORPH Articles Average Week Get Orphazyme A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Theratechnologies News Today Viracta Therapeutics News Today ImmunoPrecise Antibodies News Today Daré Bioscience News Today Apollomics News Today Aprea Therapeutics News Today Lipocine News Today DURECT News Today Acurx Pharmaceuticals News Today NRx Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORPH) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBill Gates is all about this tiny $2 stockTimothy SykesThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsUrgent Nvidia WarningAltimetryCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orphazyme A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.